TBK1 promotes cancer cell proliferation via CCL5 and IL-6 mediated STAT3 activation, and inhibition of TBK1 overcomes MEKi resistance in KRAS mutant NSCLC and NRAS mutant melanoma cells 154, 155. Here, STAT3 is linked to non-small cell lung carcinoma.